search
Back to results

Varenicline Smoking Cessation Treatment for Methadone Maintenance Patients

Primary Purpose

Tobacco Use Disorder, Medication Adherence

Status
Completed
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Varenicline
Sponsored by
Albert Einstein College of Medicine
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Tobacco Use Disorder focused on measuring Smoking, Substance-Related Disorders, medication adherence, Methadone

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Age 18 years or older
  • English speaking
  • Smoked at least 100 cigarettes/lifetime
  • Smoke 5 or more cigarettes per day
  • Interested in quitting smoking (preparation or contemplation stage of change)
  • Enrolled in Einstein/Montefiore methadone program for 12 weeks or more
  • Receiving methadone in clinic three, four, five or six times per week
  • No more than 2 methadone clinic misses in prior 14 days
  • Agree to use contraception for the duration of the trial (among women with reproductive potential)
  • Willing to participate in all study components
  • Able to provide informed consent

Exclusion Criteria:

  • Serious or unstable HIV/AIDS, liver, cardiovascular, or pulmonary disease
  • Psychiatric instability
  • Women who are pregnant, breastfeeding, or contemplating pregnancy
  • Creatinine clearance <30 mL/min

Sites / Locations

  • Albert Einstein College of Medicine

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Experimental

Arm Label

Varenicline treatment as usual (TAU)

Varenicline directly observed therapy

Arm Description

Subjects in the TAU arm will self administer varenicline for 12 weeks.

Subjects in the directly observed therapy (DOT) arm will receive varenicline directly administered by methadone clinic nurses 4-6 times per week at the same time as they receive methadone, as well as individually packaged take-home doses for self administration on evenings/weekends.

Outcomes

Primary Outcome Measures

Varenicline Adherence as Measured by Pill Count
Pill count adherence, measured as pills taken divided by pills dispensed, analyzed as a continuous measure

Secondary Outcome Measures

Tobacco Abstinence Biochemically Verified With Expired Carbon Monoxide (CO) < 8 p.p.m. at 12 Weeks
Number of participants achieving self reported, seven day point prevalence abstinence, biochemically verified with expired carbon monoxide (CO) < 8 p.p.m., missing = smoking
Tobacco Abstinence Biochemically Verified With Expired Carbon Monoxide (CO) < 8 p.p.m. at 24 Weeks
Number of participants achieving self reported, seven day point prevalence abstinence, biochemically verified with expired carbon monoxide (CO) < 8 p.p.m.

Full Information

First Posted
June 21, 2011
Last Updated
March 9, 2021
Sponsor
Albert Einstein College of Medicine
Collaborators
National Institute on Drug Abuse (NIDA)
search

1. Study Identification

Unique Protocol Identification Number
NCT01378858
Brief Title
Varenicline Smoking Cessation Treatment for Methadone Maintenance Patients
Official Title
Varenicline Smoking Cessation Treatment for Methadone Maintenance Patients
Study Type
Interventional

2. Study Status

Record Verification Date
March 2021
Overall Recruitment Status
Completed
Study Start Date
July 2011 (undefined)
Primary Completion Date
July 2015 (Actual)
Study Completion Date
July 2015 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Albert Einstein College of Medicine
Collaborators
National Institute on Drug Abuse (NIDA)

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
This randomized trial will evaluate whether varenicline directly observed therapy provided at a methadone clinic is more efficacious than self-administered varenicline for promoting smoking cessation and enhancing adherence.
Detailed Description
There is a marked prevalence of tobacco use and tobacco-related disease among methadone maintenance patients. Varenicline's demonstrated efficacy may not be generalizable to methadone maintained smokers because of poor adherence, which is highly prevalent among drug users. Adherence to smoking cessation medication is strongly associated with cessation, and is one of the few factors shown to increase cessation among methadone maintained smokers, but strategies to promote smoking cessation medication adherence have not been evaluated in methadone patients. Based on the Information, Motivation, and Behavior model, the investigators plan a directly observed therapy (DOT)-based intervention targeting behavioral skills necessary for optimal adherence. Because methadone clinic-based DOT interventions have been shown to improve medication adherence and clinical outcomes in HIV and TB, the investigators plan to determine in a randomized trial whether DOT varenicline provided at a methadone clinic is more efficacious than self-administered varenicline for promoting smoking cessation and enhancing adherence. The investigators will also evaluate moderating effects of drug and alcohol use and psychiatric symptoms on DOT effects. The investigators hypothesize subjects in the mDOT arm will have greater 7 day point prevalence abstinence at 12 weeks, reduction in cigarettes/day, time to first daily cigarette, ≥ 24 hour quit attempts, and 7 day point prevalence abstinence at 24 weeks compared to subjects receiving self administered varenicline. The investigators also hypothesize that adherence in the mDOT arm will be higher than in the TAU arm. Lastly the investigators hypothesize that ongoing illicit drug use and psychiatric symptoms will moderate the effect of mDOT on adherence.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Tobacco Use Disorder, Medication Adherence
Keywords
Smoking, Substance-Related Disorders, medication adherence, Methadone

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
100 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Varenicline treatment as usual (TAU)
Arm Type
Experimental
Arm Description
Subjects in the TAU arm will self administer varenicline for 12 weeks.
Arm Title
Varenicline directly observed therapy
Arm Type
Experimental
Arm Description
Subjects in the directly observed therapy (DOT) arm will receive varenicline directly administered by methadone clinic nurses 4-6 times per week at the same time as they receive methadone, as well as individually packaged take-home doses for self administration on evenings/weekends.
Intervention Type
Drug
Intervention Name(s)
Varenicline
Other Intervention Name(s)
Chantix
Intervention Description
Varenicline, titrated to 1 mg twice daily, will be given to participants in both study arms for 12 weeks.
Primary Outcome Measure Information:
Title
Varenicline Adherence as Measured by Pill Count
Description
Pill count adherence, measured as pills taken divided by pills dispensed, analyzed as a continuous measure
Time Frame
Weeks 0-1, 1-2, 2-3, 4-6, 7-9, 10-12
Secondary Outcome Measure Information:
Title
Tobacco Abstinence Biochemically Verified With Expired Carbon Monoxide (CO) < 8 p.p.m. at 12 Weeks
Description
Number of participants achieving self reported, seven day point prevalence abstinence, biochemically verified with expired carbon monoxide (CO) < 8 p.p.m., missing = smoking
Time Frame
Week 12 of treatment
Title
Tobacco Abstinence Biochemically Verified With Expired Carbon Monoxide (CO) < 8 p.p.m. at 24 Weeks
Description
Number of participants achieving self reported, seven day point prevalence abstinence, biochemically verified with expired carbon monoxide (CO) < 8 p.p.m.
Time Frame
24 weeks

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Age 18 years or older English speaking Smoked at least 100 cigarettes/lifetime Smoke 5 or more cigarettes per day Interested in quitting smoking (preparation or contemplation stage of change) Enrolled in Einstein/Montefiore methadone program for 12 weeks or more Receiving methadone in clinic three, four, five or six times per week No more than 2 methadone clinic misses in prior 14 days Agree to use contraception for the duration of the trial (among women with reproductive potential) Willing to participate in all study components Able to provide informed consent Exclusion Criteria: Serious or unstable HIV/AIDS, liver, cardiovascular, or pulmonary disease Psychiatric instability Women who are pregnant, breastfeeding, or contemplating pregnancy Creatinine clearance <30 mL/min
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Shadi Nahvi, M.D., M.S.
Organizational Affiliation
Albert Einstein College of Medicine
Official's Role
Principal Investigator
Facility Information:
Facility Name
Albert Einstein College of Medicine
City
Bronx
State/Province
New York
ZIP/Postal Code
10467
Country
United States

12. IPD Sharing Statement

Citations:
PubMed Identifier
32857445
Citation
Nahvi S, Adams TR, Ning Y, Zhang C, Arnsten JH. Effect of varenicline directly observed therapy versus varenicline self-administered therapy on varenicline adherence and smoking cessation in methadone-maintained smokers: a randomized controlled trial. Addiction. 2021 Apr;116(4):902-913. doi: 10.1111/add.15240. Epub 2020 Oct 13.
Results Reference
derived
PubMed Identifier
24928218
Citation
Nahvi S, Segal KS, Litwin AH, Arnsten JH. Rationale and design of a randomized controlled trial of varenicline directly observed therapy delivered in methadone clinics. Addict Sci Clin Pract. 2014 Jun 13;9(1):9. doi: 10.1186/1940-0640-9-9.
Results Reference
derived

Learn more about this trial

Varenicline Smoking Cessation Treatment for Methadone Maintenance Patients

We'll reach out to this number within 24 hrs